SECURITIES AND EXCHANGE COMMISSION

                             WASHINGTON, D.C. 20549

                                    FORM 8-K


                                 CURRENT REPORT

                     Pursuant to Section 13 or 15(d) of the

                        Securities Exchange Act of 1934

               Date of Report (Date of earliest event reported):
                      November 7, 2000 (November 2, 2000)


                          BioMarin Pharmaceutical Inc.
             (Exact name of registrant as specified in its charter)




Delaware                             000-26727                   68-0397820
(State or other jurisdiction of      (Commission               (IRS Employer
incorporation)                       File Number)            Identification No.)


371 Bel Marin Keys Boulevard,                                       94949
        Suite 210                                                (Zip Code)
   Novato, California
   (Address of principal
   executive offices)
                                  (415) 884-6700
                           (Registrant's telephone number,
                                  including area code)

















Item 5.  Other Events

Resignation of Dr. John C. Klock as director and consultant.

On November 2, 2000, Dr. John C. Klock  submitted his resignation as a member of
the BioMarin  Pharmaceutical  Inc. (the  "Company")  Board of Directors and as a
consultant  to  the  Company.  Dr.  Klock's  resignation  indicated  that  he is
resigning in order to devote  substantially  all of his working efforts to other
ventures, particularly early stage companies.

Dr. Klock  resigned his post as  president of the Company  effective  July 31 of
this year but continued to serve as a consultant  to ensure a smooth  transition
of his responsibilities to other members of the Company's executive team.

The  Company's  Board of  Directors  intends to initiate a search to identify an
appropriate replacement for Dr. Klock on the Board of Directors.

Item 7.               Financial Statements and Exhibits

None.






                                   SIGNATURES

                  Pursuant to the requirements of the Securities Exchange Act of
1934,  the  registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.

                                     BioMarin Pharmaceutical Inc.


                                     By: /s/ Fredric D. Price
                                         ---------------------------------------
                                             Fredric D. Price
                                             Chairman and
                                             Chief Executive Officer

Date:  November 7, 2000